Skip to main content

Animations

MJFF Publications

6201 - 6210 of 9145 Results
Title
Year
  • Year
  • 2018
  • 2014
  • 2013
  • 2018
  • 2016
  • 2017
  • 2006
  • 2017
  • 2017
  • 2022
  • Summary Details
    OPEN
    Title: The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20180248
    Citation Count: 219
  • Summary Details
    OPEN
    Title: Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-sa
    DOI - Digital Object Identifier: 10.1016/j.nbd.2014.06.009
    Citation Count: 227
  • Summary Details
    OPEN
    Title: Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
    Journal Name: PLoS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc0
    DOI - Digital Object Identifier: 10.1371/journal.pone.0080705
    Citation Count: 187
  • Summary Details
    OPEN
    Title: Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.27361
    Citation Count: 205
  • Summary Details
    OPEN
    Title: Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20160557
    Citation Count: 182
  • Summary Details
    OPEN
    Title: Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20170803
    Citation Count: 179
  • Crossroads in GDNF therapy for Parkinson's disease
    2006
    Summary Details
    RESTRICTED
    Title: Crossroads in GDNF therapy for Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.20861
    Citation Count: 174
  • Summary Details
    OPEN
    Title: Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20170802
    Citation Count: 166
  • Summary Details
    OPEN
    Title: Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000004609
    Citation Count: 152
  • Summary Details
    OPEN
    Title: Six Action Steps to Address Global Disparities in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1783
    Citation Count: 144
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.